AEON Biopharma
AEON
19 hedge funds and large institutions have $56.8M invested in AEON Biopharma in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
94% more capital invested
Capital invested by funds: $29.3M → $56.8M (+$27.5M)
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
27% more funds holding
Funds holding: 15 → 19 (+4)
9.69% more ownership
Funds ownership: 13.63% → 23.32% (+9.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$21.6M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$96.8K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$90K |
| 4 |
State Street
Boston,
Massachusetts
|
+$56.2K |
| 5 |
JP Morgan Chase
New York
|
+$38.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
-$3.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$59.4K |
| 3 |
FAM
Formidable Asset Management
Cincinnati,
Ohio
|
-$34.1K |
| 4 |
Goldman Sachs
New York
|
-$32.1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.01K |
AEON Hedge Fund Activity: Q4 2023 in Review
19 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q4 2023, worth a combined $56.8M — up 94% from $29.3M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new AEON positions and 2 closed out — a net gain of 4 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Polar Asset Management Partners, opening a new position worth an estimated $21.6M. The largest seller was Rivernorth Capital Management, exiting entirely with an estimated $3.4M sold.
- 19 institutional investors held AEON Biopharma (AEON) as of Q4 2023, up from 15 in Q3 2023.
- Funds reported $56.8M of AEON Biopharma stock for Q4 2023, up 94% quarter-over-quarter.
- 6 funds opened new AEON Biopharma positions in Q4 2023 and 2 closed out, a net change of +4 holders.
- The largest AEON Biopharma buyer in Q4 2023 was Polar Asset Management Partners, an estimated $21.6M added.
- The largest AEON Biopharma seller in Q4 2023 was Rivernorth Capital Management, an estimated $3.4M sold.
Based on aggregated 13F filings for Q4 2023.